– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA 50 ; in patients with AR L702H mutations, 3 of 5 achieved PSA 50 – – ARV-766 was well-tolerated, and activity in a heavily pre-treated patient population supports its potential as a treatment in earlier line settings such